Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ABBV

Abbvie Inc

Jan 22 • 04:00PM ET

169.20

Dollar change -3.41
Percentage change -1.98	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: JNJ PFE MRK LLY BMY GILD AMGN REGN VRTX BIIB

| Held by: VTI VOO SPY IVV SCHD VTV XLV VIG VYM VHT

Scroll to Statements

Index	S&P 500	P/E	59.01	EPS (ttm)	2.87	Insider Own	0.08%	Shs Outstand	1.77B	Perf Week	-3.62%
Market Cap	299.00B	Forward P/E	13.89	EPS next Y	12.18	Insider Trans	-4.61%	Shs Float	1.77B	Perf Month	-2.21%
Income	5.08B	PEG	7.23	EPS next Q	2.99	Inst Own	72.96%	Short Float	0.96%	Perf Quarter	-10.41%
Sales	55.53B	P/S	5.38	EPS this Y	-1.14%	Inst Trans	-0.06%	Short Ratio	2.63	Perf Half Y	-2.54%
Book/sh	3.41	P/B	49.57	EPS next Y	10.90%	ROA	3.63%	Short Interest	17.00M	Perf Year	2.69%
Cash/sh	4.12	P/C	41.04	EPS next 5Y	8.16%	ROE	56.06%	52W Range	153.58 - 207.32	Perf YTD	-4.78%
Dividend Est.	6.17 (3.65%)	P/FCF	19.19	EPS past 5Y	-5.77%	ROI	7.87%	52W High	-18.39%	Beta	0.56
Dividend TTM	6.29 (3.72%)	Quick Ratio	0.54	Sales past 5Y	14.31%	Gross Margin	69.87%	52W Low	10.17%	ATR (14)	3.69
Dividend Ex-Date	Jan 15, 2025	Current Ratio	0.65	EPS Y/Y TTM	-21.61%	Oper. Margin	30.61%	RSI (14)	37.26	Volatility	2.25% 1.86%
Employees	50000	Debt/Eq	11.78	Sales Y/Y TTM	0.72%	Profit Margin	9.15%	Recom	1.81	Target Price	203.56
Option/Short	Yes / Yes	LT Debt/Eq	9.70	EPS Q/Q	-12.27%	Payout	220.33%	Rel Volume	1.31	Prev Close	172.61
Sales Surprise	1.24%	EPS Surprise	2.74%	Sales Q/Q	3.83%	Earnings	Jan 31 BMO	Avg Volume	6.48M	Price	169.20
SMA20	-4.13%	SMA50	-3.98%	SMA200	-5.28%	Trades		Volume	8,493,465	Change	-1.98%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-24	Resumed	BofA Securities	Neutral	$191
Dec-05-24	Downgrade	Daiwa Securities	Outperform → Neutral	$180
Nov-22-24	Upgrade	Leerink Partners	Market Perform → Outperform	$206
Nov-15-24	Initiated	Wolfe Research	Outperform	$205
Nov-04-24	Upgrade	Argus	Hold → Buy
Oct-17-24	Initiated	Bernstein	Mkt Perform	$203
Jun-05-24	Upgrade	HSBC Securities	Hold → Buy	$185
May-17-24	Initiated	Cantor Fitzgerald	Overweight	$200
Jan-29-24	Upgrade	William Blair	Mkt Perform → Outperform
Dec-18-23	Downgrade	HSBC Securities	Buy → Hold
Dec-11-23	Upgrade	Goldman	Neutral → Buy
Nov-09-23	Initiated	Deutsche Bank	Hold	$150
Oct-30-23	Upgrade	Barclays	Equal Weight → Overweight	$160 → $170
Oct-20-23	Resumed	UBS	Neutral	$157 → $150
Sep-29-23	Initiated	Raymond James	Outperform	$177
Jul-25-23	Initiated	William Blair	Mkt Perform
Jul-14-23	Initiated	HSBC Securities	Buy	$167
Apr-05-23	Downgrade	Argus	Buy → Hold
Mar-01-23	Initiated	Guggenheim	Buy	$172
Feb-22-23	Downgrade	Wolfe Research	Outperform → Peer Perform

Show Previous Ratings

Jan-22-25 02:58PM	Why Is AbbVie Inc. (ABBV) Among the Best Large-Cap Value Stocks to Buy in 2025? (Insider Monkey)
01:44PM	Is AbbVie Inc. (ABBV) the Best Stock to Invest In For Steady Dividends? (Insider Monkey)
12:03PM	Downside risk from talc lawsuit, Stelara generic competition is 'manageable': JNJ CFO Joe Wolk (Yahoo Finance)
Jan-21-25 06:22PM	Got $1,500? 3 Healthcare Stocks to Buy and Hold Forever (Motley Fool)
04:04PM	Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere Here's Why (Investor's Business Daily)
07:10AM	Loading…
07:10AM	Got $500? 2 Pharmaceutical Stocks to Buy and Hold Forever (Motley Fool)
06:01AM	The Art of Valuation: Discovering AbbVie Inc's Intrinsic Value (GuruFocus.com)
04:17AM	3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever (Motley Fool)
Jan-20-25 07:50AM	AbbVie Inc. (ABBV): A Bull Case Theory (Insider Monkey)
Jan-19-25 12:01PM	Top Wall Street Analyst Says Dump The Magnificent 7 And Go All In On These Three Big Pharma Dividend Stocks (Benzinga)
Jan-18-25 05:01PM	Count on Dividend King Pepsi (PEP) for Stability in a Volatile Market (TipRanks)
11:21AM	Why Is AbbVie Inc. (ABBV) Among Louis Navelliers Top Long-term Stock Picks? (Insider Monkey)
08:20AM	Ozempic, Xtandi among next 15 drugs selected for U.S. price talks (TipRanks)
Jan-17-25 12:15PM	Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations (Benzinga)
09:46AM	Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations (Yahoo Finance)
05:45PM	Loading…
Jan-16-25 05:45PM	Why the Market Dipped But AbbVie (ABBV) Gained Today (Zacks)
11:41AM	Humira Holds Firm at 72% Market Share-AbbVie Fends Off Biosimilar Surge (GuruFocus.com)
03:56AM	JPM25: The FDAs future, AbbVies second thoughts and Lillys lesson (BioPharma Dive)
Jan-15-25 07:30PM	JP Morgan 2025: AbbVie counts on Skyrizi and Rinvoq to fill Humira-sized hole (Clinical Trials Arena)
04:04PM	AbbVie's $3.5 Billion Blow: Can Bold Bets Revive Its Profit Forecasts? (GuruFocus.com)
10:47AM	AbbVie and Simcere Zaiming link to develop trispecific antibody (Pharmaceutical Technology)
Jan-14-25 01:38PM	AbbVie Inc. (ABBV): An Undervalued Dividend Kings Stock to Invest in Now? (Insider Monkey)
09:25AM	AbCellera expands collaboration with AbbVie (TipRanks)
09:00AM	AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know (Zacks)
08:15AM	2 Brilliant Dividend Growth Stocks That Can Supercharge Your Portfolio (Motley Fool)
06:01AM	AbbVie Inc: An Exploration into Its Intrinsic Value (GuruFocus.com)
05:15AM	3 High-Yielding Dividend Stocks That Could Be Ideal Investments for Retirees (Motley Fool)
Jan-13-25 03:13PM	Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal (The Wall Street Journal)
09:05AM	Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma (PR Newswire)
09:00AM	AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology (Business Wire)
09:00AM	Loading…
09:00AM	AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma (PR Newswire)
09:00AM	3 High-Yield Dividend Stocks to Buy in 2025 (Motley Fool)
08:31AM	AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program (PR Newswire)
Jan-11-25 03:38AM	3 Incredible Dividend Stocks to Buy in 2025 (Motley Fool)
Jan-10-25 12:04PM	Top Stock Movers Now: Constellation Brands, Allstate, Delta Air Lines, and More (Investopedia)
11:10AM	AbbVie Takes $3.5B Impairment Charge for Failed Schizophrenia Drug (Investopedia)
09:16AM	AbbVie to Post $3.5 Billion Impairment Charge on Failed Cerevel Drug (The Wall Street Journal)
06:43AM	Pfizers PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets (BioPharma Dive)
Jan-09-25 08:00AM	AbbVie to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-07-25 05:45PM	AbbVie (ABBV) Stock Moves -0.32%: What You Should Know (Zacks)
12:10PM	Will AbbVie (ABBV) Beat Estimates Again in Its Next Earnings Report? (Zacks)
08:00AM	CoolMonth is Back With Deals on CoolSculpting Elite by Allergan Aesthetics (PR Newswire)
06:01AM	Beyond Market Price: Uncovering AbbVie Inc's Intrinsic Value (GuruFocus.com)
04:41AM	ALS drugs from Denali, Calico come up short, marking setback for Healey trial (BioPharma Dive)
Jan-06-25 04:45PM	AbbVie cuts 2024 profit forecast on acquisition expenses (Reuters)
05:45AM	The Smartest Dividend Stocks to Buy With $500 Right Now (Motley Fool)
04:17AM	2 No-Brainer Dividend Stocks to Buy With $250 in 2025 (Motley Fool)
Jan-04-25 05:19AM	3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade (Motley Fool)
Jan-03-25 08:00AM	AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call (PR Newswire)
Jan-02-25 02:10PM	What RFK Jr.s Dislike for Drug TV Commercials Could Mean for the Ad Industry (The Wall Street Journal)
06:37AM	Beyond Market Price: Uncovering AbbVie Inc's Intrinsic Value (GuruFocus.com)
Jan-01-25 03:30AM	Drug-Trial Results Could Shake Up Pharma Stocks in 2025. Watch Eli Lilly, Pfizer, and More. (Barrons.com)
Dec-31-24 05:45PM	AbbVie (ABBV) Gains As Market Dips: What You Should Know (Zacks)
12:00PM	AbbVie (ABBV) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
11:12AM	10 stocks retail investors craved in 2024 (Yahoo Finance)
09:30AM	Brokers Suggest Investing in AbbVie (ABBV): Read This Before Placing a Bet (Zacks)
09:00AM	AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
05:36AM	Is AbbVie Inc. (ABBV) the Best Dividend Stock of 2024? (Insider Monkey)
Dec-30-24 05:17PM	Is AbbVie Inc. (ABBV) the Best Pharma Dividend Stock to Buy In 2024? (Insider Monkey)
02:10PM	Is AbbVie Inc. (ABBV) the Best Stock for 10 Years? (Insider Monkey)
05:30AM	Credit Spreads Havent Looked This Good Since the 2000s. Can They Get Better? (The Wall Street Journal)
04:19AM	Is AbbVie Inc. (ABBV) the Best Dividend Growth Stock to Buy and Hold in 2025? (Insider Monkey)
Dec-26-24 09:00AM	Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook (GlobeNewswire)
05:35AM	The Smartest Dividend Stocks to Buy With $1,000 Right Now (Motley Fool)
Dec-24-24 05:45PM	AbbVie (ABBV) Rises Yet Lags Behind Market: Some Facts Worth Knowing (Zacks)
09:56AM	Why AbbVie Inc. (ABBV) Is Among the Best Stocks to Buy and Hold for 3 Years? (Insider Monkey)
06:01AM	Invest with Confidence: Intrinsic Value Unveiled of AbbVie Inc (GuruFocus.com)
Dec-23-24 08:48AM	AbbVie (ABBV) Benefitted from Top-Line Growth From Its Immunosuppressive Drugs (Insider Monkey)
08:30AM	Is AbbVie Stock a Buy? (Motley Fool)
04:32AM	2 Excellent Dividend Stocks to Buy on the Dip (Motley Fool)
Dec-22-24 06:50AM	2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off (Motley Fool)
Dec-21-24 11:31PM	Is AbbVie Inc. (ABBV) the Best Dividend Stock for Steady Income? (Insider Monkey)
06:48AM	3 Fantastic Stocks That Could Enjoy a Santa Claus Rally (Motley Fool)
Dec-19-24 08:00AM	AbbVie's atogepant and onabotulinumtoxinA receive strong recommendations in the newly updated Canadian Headache Society (CHS) Migraine Prevention Guideline (PR Newswire)
06:00AM	2 Top Dividend Stocks to Buy and Hold Through 2025 and Beyond (Motley Fool)
04:40AM	Is AbbVie Inc. (ABBV) the Safest Dividend Stock to Invest In Now? (Insider Monkey)
Dec-18-24 09:00AM	Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know (Zacks)
08:49AM	AbbVies tavapadon achieves positive topline results in Phase III TEMPO-2 trial (Clinical Trials Arena)
Dec-17-24 08:00AM	AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back? (Investor's Business Daily)
Dec-16-24 05:45PM	AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors (Zacks)
04:02AM	AbbVie to acquire Nimble Therapeutics for $200m (Pharmaceutical Technology)
03:00AM	3 closely watched drugs that failed in the clinic (Pharma Voice)
Dec-15-24 05:35AM	Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever (Motley Fool)
Dec-13-24 02:00PM	This Drugmaker's (ABBV) Parkinson's Medication Just Cleared A Key Hurdle Is It Primed For A Monster Year In 2025? (Benzinga)
09:15AM	AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline (PR Newswire)
06:00AM	AbbVie to acquire Roche spinout Nimble in immune drug deal (BioPharma Dive)
Dec-12-24 07:41AM	Why AbbVie Inc. (ABBV) Is the Best Safe Stock to Buy According to Analysts? (Insider Monkey)
06:00AM	1 Magnificent S&P 500 Dividend Stock Down 14% to Buy and Hold Forever (Motley Fool)
Dec-11-24 09:15AM	AbbVie Completes Acquisition of Aliada Therapeutics (PR Newswire)
05:45AM	BenevolentAI restructures; Lilly preps $15B buyback program (BioPharma Dive)
Dec-10-24 11:17PM	Why Is AbbVie Inc. (ABBV) Among the Best Cosmetic Surgery and Aesthetics Stocks to Invest In Now? (Insider Monkey)
12:08PM	Hope for Parkinsons disease symptoms is found in late-stage drug study (Fortune)
06:00AM	Beyond Market Price: Uncovering AbbVie Inc's Intrinsic Value (GuruFocus.com)
05:20AM	AbbVies Phase III trial of Parkinsons disease treatment meets primary endpoint (Clinical Trials Arena)
Dec-09-24 12:00PM	Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (PR Newswire)
11:16AM	AbbVie's Early Parkinson's Candidate Hits Primary Goal In Pivotal Late-Stage Study (Benzinga)
08:00AM	AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease (PR Newswire)
03:00AM	Endometriosis drug research, long underfunded, confronts familiar problems in womens health (BioPharma Dive)
Dec-08-24 03:00PM	AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients (PR Newswire)
Dec-07-24 07:00PM	Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) (PR Newswire)

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Buckbee Kevin K	SVP, CONTROLLER	Dec 16 '24	Option Exercise	93.50	1,800	168,300	8,783	Dec 18 05:00 PM
Buckbee Kevin K	SVP, CONTROLLER	Dec 16 '24	Sale	172.24	1,800	310,032	6,983	Dec 18 05:00 PM
Buckbee Kevin K	Officer	Dec 16 '24	Proposed Sale	172.25	1,800	310,045		Dec 16 05:34 PM
Hudson Thomas J	Officer	Aug 08 '24	Proposed Sale	189.08	49,170	9,297,210		Aug 08 05:40 PM
GONZALEZ RICHARD A	EXECUTIVE CHAIRMAN OF BOARD	Aug 05 '24	Sale	186.52	66,500	12,403,580	446,599	Aug 07 05:00 PM
Hudson Thomas J	Officer	Aug 07 '24	Proposed Sale	187.62	101,886	19,115,380		Aug 07 04:22 PM
GONZALEZ RICHARD A	Officer	Aug 05 '24	Proposed Sale	187.36	66,500	12,459,360		Aug 05 10:54 AM
GONZALEZ RICHARD A	EXECUTIVE CHAIRMAN OF BOARD	Jul 17 '24	Option Exercise	77.49	282,845	21,919,048	795,944	Jul 19 04:40 PM
GONZALEZ RICHARD A	EXECUTIVE CHAIRMAN OF BOARD	Jul 17 '24	Sale	175.00	282,845	49,497,875	513,099	Jul 19 04:40 PM
Donoghoe Nicholas	EVP, CHIEF BUS/STRAT OFFICER	Mar 20 '24	Sale	176.30	21,082	3,716,757	55,903	Mar 22 05:00 PM
Stewart Jeffrey Ryan	EVP, CHIEF COMMERCIAL OFFICER	Mar 18 '24	Option Exercise	61.36	26,110	1,602,110	119,890	Mar 20 05:00 PM
Stewart Jeffrey Ryan	EVP, CHIEF COMMERCIAL OFFICER	Mar 18 '24	Sale	178.79	58,949	10,539,508	60,941	Mar 20 05:00 PM
RICHMOND TIMOTHY J.	EVP, CHIEF HR OFFICER	Mar 01 '24	Option Exercise	61.36	45,700	2,804,152	89,517	Mar 05 05:30 PM
RICHMOND TIMOTHY J.	EVP, CHIEF HR OFFICER	Mar 01 '24	Sale	177.27	75,680	13,415,503	13,837	Mar 05 05:30 PM
Reents Scott T	EVP, CHIEF FINANCIAL OFFICER	Feb 23 '24	Option Exercise	61.36	14,140	867,630	41,205	Mar 01 05:50 PM
Reents Scott T	EVP, CHIEF FINANCIAL OFFICER	Feb 23 '24	Sale	177.44	14,140	2,509,002	27,065	Mar 01 05:50 PM
Buckbee Kevin K	SVP, CONTROLLER	Feb 29 '24	Sale	176.65	5,144	908,688	6,983	Mar 01 05:50 PM
Michael Robert A.	PRES & CHIEF OPERATING OFFICER	Feb 29 '24	Option Exercise	58.30	21,560	1,257,012	167,524	Mar 01 05:50 PM
Michael Robert A.	PRES & CHIEF OPERATING OFFICER	Feb 29 '24	Sale	176.45	68,879	12,153,957	98,645	Mar 01 05:50 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 29 '24	Sale	177.39	9,891	1,754,555	10,397	Mar 01 05:50 PM
GONZALEZ RICHARD A	CHAIRMAN OF THE BOARD AND CEO	Feb 28 '24	Sale	177.27	138,616	24,572,458	519,099	Mar 01 05:50 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 23 '24	Option Exercise	137.36	13,753	1,889,115	41,926	Feb 27 05:10 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 23 '24	Sale	177.51	13,753	2,441,295	28,173	Feb 27 05:10 PM
SALEKI-GERHARDT AZITA	EVP, CHIEF OPERATIONS OFFICER	Feb 21 '24	Option Exercise	58.88	52,870	3,112,986	296,814	Feb 23 05:00 PM
SALEKI-GERHARDT AZITA	EVP, CHIEF OPERATIONS OFFICER	Feb 21 '24	Sale	173.71	52,870	9,184,048	243,944	Feb 23 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABBV

Abbvie Inc

Upgrade your FINVIZ experience